JP6966425B2 - 抗がん剤としての複素環式の限定された三環系スルホンアミド - Google Patents
抗がん剤としての複素環式の限定された三環系スルホンアミド Download PDFInfo
- Publication number
- JP6966425B2 JP6966425B2 JP2018512944A JP2018512944A JP6966425B2 JP 6966425 B2 JP6966425 B2 JP 6966425B2 JP 2018512944 A JP2018512944 A JP 2018512944A JP 2018512944 A JP2018512944 A JP 2018512944A JP 6966425 B2 JP6966425 B2 JP 6966425B2
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- hydrogen
- alkyl
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1C(*C(CCC2)C(**C3C*CCC3)CC*(*)CCC2(*)[U])CC(*)CCC(C)(*)C=CC1 Chemical compound CC1C(*C(CCC2)C(**C3C*CCC3)CC*(*)CCC2(*)[U])CC(*)CCC(C)(*)C=CC1 0.000 description 5
- PUYUBCVYXWGLFB-QCDXTXTGSA-N C/C=C\C1=C(C=C)N(C(COC=C)C(CNS(C2=CCCC=C2)(=O)=O)O)c2ccccc2CC1 Chemical compound C/C=C\C1=C(C=C)N(C(COC=C)C(CNS(C2=CCCC=C2)(=O)=O)O)c2ccccc2CC1 PUYUBCVYXWGLFB-QCDXTXTGSA-N 0.000 description 1
- JHVNSRJPBXPZJU-UHFFFAOYSA-N FC(Oc(cc1)ccc1S)(F)F Chemical compound FC(Oc(cc1)ccc1S)(F)F JHVNSRJPBXPZJU-UHFFFAOYSA-N 0.000 description 1
- YMJQEHZINDEUPT-UHFFFAOYSA-N FC(Oc(cc1)ccc1[SH3+2])(F)F Chemical compound FC(Oc(cc1)ccc1[SH3+2])(F)F YMJQEHZINDEUPT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216168P | 2015-09-09 | 2015-09-09 | |
| US62/216,168 | 2015-09-09 | ||
| PCT/US2016/050685 WO2017044567A1 (en) | 2015-09-09 | 2016-09-08 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526416A JP2018526416A (ja) | 2018-09-13 |
| JP2018526416A5 JP2018526416A5 (enExample) | 2019-11-07 |
| JP6966425B2 true JP6966425B2 (ja) | 2021-11-17 |
Family
ID=56940436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512944A Expired - Fee Related JP6966425B2 (ja) | 2015-09-09 | 2016-09-08 | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10221158B2 (enExample) |
| EP (1) | EP3347350A1 (enExample) |
| JP (1) | JP6966425B2 (enExample) |
| CN (1) | CN108349943A (enExample) |
| CA (1) | CA2997769A1 (enExample) |
| WO (1) | WO2017044567A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106458916A (zh) | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| EP3116860B1 (en) | 2014-03-11 | 2018-02-07 | Icahn School of Medicine at Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| EP3347355B1 (en) | 2015-09-09 | 2022-07-13 | Icahn School of Medicine at Mount Sinai | Heterotricyclic sulfonamides as anti-cancer agents |
| WO2021150695A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents |
| US20230020161A1 (en) * | 2020-02-28 | 2023-01-19 | Rappta Therapeutics Oy | Tricyclic Modulators of PP2A |
| EP4121031A4 (en) * | 2020-03-20 | 2024-03-27 | Atux Iskay LLC | 3-DIARYLMETHYLENE AND THEIR USE |
| CN114272378B (zh) * | 2020-09-27 | 2023-06-23 | 四川大学华西医院 | 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途 |
| EP4288414A1 (en) * | 2021-02-08 | 2023-12-13 | Rappta Therapeutics Oy | Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same |
| EP4387962A4 (en) * | 2021-08-18 | 2025-08-13 | Atux Iskay Llc | 2-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS USED AS ANTICANCER, ANTI-INFLAMMATORY, ANTIFIBROTIC, AND NEUROPROTECTIVE AGENTS |
| PE20250934A1 (es) * | 2022-08-04 | 2025-04-02 | Rappta Therapeutics Oy | Compuestos aromaticos para su uso como moduladores de la proteina fosfatasa 2a (pp2a) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| DE69431470T2 (de) | 1993-07-26 | 2003-08-14 | Eisai Co., Ltd. | Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring |
| EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| WO1999043683A1 (en) | 1998-02-27 | 1999-09-02 | Eisai Co., Ltd. | Heterocycle-fused benzothiazine derivatives |
| MY120281A (en) | 2000-09-20 | 2005-09-30 | Schering Corp | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| JP4428053B2 (ja) | 2002-02-05 | 2010-03-10 | 味の素株式会社 | ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物 |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| AU2005318465A1 (en) | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with Kv4 ion channel activity |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| WO2008121859A1 (en) | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
| AU2012296528B2 (en) | 2011-08-16 | 2017-07-06 | Icahn School Of Medicine At Mount Sinai | Tricyclic compounds as anticancer agents |
| US9701676B2 (en) | 2012-08-24 | 2017-07-11 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| CA2901493A1 (en) | 2013-02-19 | 2014-08-28 | Icahn School Of Medicine At Mount Sinai | Tricyclic heterocycles as anticancer agents |
| EP3116860B1 (en) | 2014-03-11 | 2018-02-07 | Icahn School of Medicine at Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| CN106458916A (zh) | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| US10450282B2 (en) | 2015-08-06 | 2019-10-22 | Icahn School Of Medicine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
| WO2017044575A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| EP3347355B1 (en) | 2015-09-09 | 2022-07-13 | Icahn School of Medicine at Mount Sinai | Heterotricyclic sulfonamides as anti-cancer agents |
| WO2017044571A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
| WO2017044572A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Ring constrained diarylamino sulfonamides as anti-cancer agents |
-
2016
- 2016-09-08 CA CA2997769A patent/CA2997769A1/en not_active Abandoned
- 2016-09-08 US US15/758,038 patent/US10221158B2/en active Active
- 2016-09-08 JP JP2018512944A patent/JP6966425B2/ja not_active Expired - Fee Related
- 2016-09-08 EP EP16766784.9A patent/EP3347350A1/en not_active Ceased
- 2016-09-08 CN CN201680063247.5A patent/CN108349943A/zh active Pending
- 2016-09-08 WO PCT/US2016/050685 patent/WO2017044567A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US10221158B2 (en) | 2019-03-05 |
| JP2018526416A (ja) | 2018-09-13 |
| US20180251444A1 (en) | 2018-09-06 |
| EP3347350A1 (en) | 2018-07-18 |
| CN108349943A (zh) | 2018-07-31 |
| WO2017044567A1 (en) | 2017-03-16 |
| CA2997769A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6966425B2 (ja) | 抗がん剤としての複素環式の限定された三環系スルホンアミド | |
| JP7461390B2 (ja) | メニン－ｍｌｌ相互作用の阻害剤 | |
| JP6955485B2 (ja) | 抗がん剤としての複素環式の限定された三環系スルホンアミド | |
| JP6871864B2 (ja) | イソオキサゾリル置換ベンズイミダゾール類 | |
| KR102659741B1 (ko) | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 | |
| CN114828959B (zh) | 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 | |
| JP6026427B2 (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| JP7091336B2 (ja) | ヒストンメチルトランスフェラーゼ阻害剤 | |
| JP7759877B2 (ja) | 治療用化合物 | |
| AU2014234909B2 (en) | Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors | |
| CN112424185A (zh) | 含苯环的化合物、其制备方法及应用 | |
| TW201623307A (zh) | 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物 | |
| JP2021515773A (ja) | ＰＩ３Ｋ−γ阻害剤としてのアミノピラジンジオール化合物 | |
| JP2017512766A (ja) | 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド | |
| WO2017044575A1 (en) | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents | |
| CN117956992A (zh) | Menin-mll相互作用的抑制剂 | |
| WO2017044571A1 (en) | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents | |
| TW202333663A (zh) | Rxfp1促效劑 | |
| JP7370032B2 (ja) | Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体 | |
| WO2019129114A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 | |
| WO2021150697A1 (en) | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents | |
| JP7349572B2 (ja) | 架橋環縮合ホルミルピリジン誘導体及びその応用 | |
| CN118119607A (zh) | 作为抗癌、抗炎、抗纤维和神经保护剂的2-二芳基甲基-4-氨基四氢吡喃衍生物及相关化合物 | |
| WO2021150700A1 (en) | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents | |
| NZ717556B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190918 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210709 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210709 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210727 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210902 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210907 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210928 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211021 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6966425 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |